Michael Burkes Brophy Sells 1,381 Shares of Natera Inc (NASDAQ:NTRA) Stock

Natera Inc (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,381 shares of the company’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $24.10, for a total transaction of $33,282.10. Following the completion of the transaction, the chief financial officer now owns 21,179 shares in the company, valued at $510,413.90. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

  • On Tuesday, March 10th, Michael Burkes Brophy sold 787 shares of Natera stock. The stock was sold at an average price of $33.36, for a total transaction of $26,254.32.
  • On Thursday, February 27th, Michael Burkes Brophy sold 200 shares of Natera stock. The stock was sold at an average price of $40.00, for a total transaction of $8,000.00.
  • On Monday, February 3rd, Michael Burkes Brophy sold 2,251 shares of Natera stock. The stock was sold at an average price of $35.22, for a total transaction of $79,280.22.
  • On Thursday, January 2nd, Michael Burkes Brophy sold 625 shares of Natera stock. The stock was sold at an average price of $33.86, for a total transaction of $21,162.50.

Shares of NASDAQ:NTRA opened at $26.09 on Thursday. Natera Inc has a 52 week low of $16.87 and a 52 week high of $41.80. The company’s 50 day moving average is $33.35 and its two-hundred day moving average is $35.26. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.91 and a quick ratio of 2.84.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Wednesday, February 26th. The medical research company reported ($0.44) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.60) by $0.16. Natera had a negative net margin of 41.30% and a negative return on equity of 120.68%. The company had revenue of $83.20 million for the quarter, compared to the consensus estimate of $77.84 million. As a group, research analysts forecast that Natera Inc will post -2.36 earnings per share for the current year.

A number of equities research analysts have issued reports on the stock. BidaskClub lowered shares of Natera from a “buy” rating to a “hold” rating in a report on Wednesday, March 11th. Zacks Investment Research lowered shares of Natera from a “buy” rating to a “hold” rating in a report on Thursday, January 23rd. Canaccord Genuity reissued a “buy” rating and issued a $46.00 price objective on shares of Natera in a research report on Thursday, March 19th. Craig Hallum reissued a “buy” rating and issued a $49.00 price objective on shares of Natera in a research report on Thursday, December 19th. Finally, Piper Sandler increased their price objective on shares of Natera from $45.00 to $49.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $43.00.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Nuveen Asset Management LLC lifted its holdings in shares of Natera by 4.7% during the 4th quarter. Nuveen Asset Management LLC now owns 1,061,355 shares of the medical research company’s stock valued at $35,757,000 after purchasing an additional 47,836 shares in the last quarter. Norges Bank bought a new stake in Natera in the 4th quarter valued at $20,893,000. Geode Capital Management LLC boosted its stake in Natera by 10.8% in the 4th quarter. Geode Capital Management LLC now owns 916,590 shares of the medical research company’s stock valued at $30,879,000 after purchasing an additional 89,493 shares during the period. Alliancebernstein L.P. boosted its stake in Natera by 0.7% in the 4th quarter. Alliancebernstein L.P. now owns 76,000 shares of the medical research company’s stock valued at $2,560,000 after purchasing an additional 500 shares during the period. Finally, Man Group plc lifted its position in shares of Natera by 114.4% during the 4th quarter. Man Group plc now owns 182,457 shares of the medical research company’s stock valued at $6,146,000 after acquiring an additional 97,353 shares during the period. 91.88% of the stock is currently owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Story: Limitations of analyzing profit margin

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.